MM-206 |
| Catalog No.GC44227 |
STAT3 활성 억제제인 MM-206은 1.2μM의 IC50과 STAT3 SH2 도메인-포스포펩티드 상호작용을 강력하게 억제합니다. MM-206은 급성 골수성 백혈병(AML) 세포주에서 용량 의존적 세포자멸사 유도를 보여줍니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1809581-87-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MM-206 is an inhibitor of STAT3 (IC50 = 1.16 µM in an SPR-based competitive assay). It inhibits STAT3 phosphorylation induced by granulocyte colony-stimulating factor (G-CSF) in HL-60, Kasumi-1, and MOLM-13 acute myeloid leukemia (AML) cells (IC50s = 0.8, 1.9, and 1.1 µM, respectively). MM-206 induces apoptosis more potently in AML cell lines and patient-derived primary AML tumor cells than in acute lymphoblastic leukemia cells, which do not have upregulated STAT3 activity. It also slows disease progression and improves survival in an AML mouse xenograft model when administered at a dose of 30 mg/kg per day.
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *